Eylea vs Tepezza
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Eylea | US Tepezza | |
|---|---|---|
| Generic name | aflibercept | teprotumumab |
| Drug class | VEGF Inhibitor (Eye Injection) | IGF-1R Inhibitor (Biologic) |
| Treats | Wet macular degeneration, diabetic eye disease | Thyroid eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Regeneron | Amgen |
| Year approved | 2011 | 2020 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $90M | — |
| Common side effects | Eye floaters, Eye pain, Increased eye pressure, Bleeding in the eye | Muscle spasms, Nausea, Hair loss, Hearing problems |
Frequently asked questions
Is Eylea or Tepezza better?
Neither is universally "better." Eylea (aflibercept) and Tepezza (teprotumumab) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Eylea and Tepezza?
Eylea is a VEGF Inhibitor (Eye Injection) made by Regeneron, while Tepezza is a IGF-1R Inhibitor (Biologic) made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Eylea has the larger estimated TV advertising budget of the two.